These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23326531)

  • 1. KML001 displays vascular disrupting properties and irinotecan combined antitumor activities in a murine tumor model.
    Moon CH; Lee SJ; Lee HY; Lee JC; Cha H; Cho WJ; Park JW; Park HJ; Seo J; Lee YH; Song HT; Min YJ
    PLoS One; 2013; 8(1):e53900. PubMed ID: 23326531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis.
    Woo SR; Ham Y; Kang W; Yang H; Kim S; Jin J; Joo KM; Nam DH
    Biomed Res Int; 2014; 2014():747415. PubMed ID: 25295271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KML001 cytotoxic activity is associated with its binding to telomeric sequences and telomere erosion in prostate cancer cells.
    Phatak P; Dai F; Butler M; Nandakumar MP; Gutierrez PL; Edelman MJ; Hendriks H; Burger AM
    Clin Cancer Res; 2008 Jul; 14(14):4593-602. PubMed ID: 18628474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin's lymphoma: an in vitro and in vivo study.
    Yoon JS; Hwang DW; Kim ES; Kim JS; Kim S; Chung HJ; Lee SK; Yi JH; Uhm J; Won YW; Park BB; Choi JH; Lee YY
    Invest New Drugs; 2016 Feb; 34(1):1-14. PubMed ID: 26581399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model.
    Moon CH; Lee SJ; Lee HY; Dung le TK; Cho WJ; Cha H; Park JW; Min YJ
    Invest New Drugs; 2014 Jun; 32(3):400-11. PubMed ID: 24202729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.
    Troiani T; Serkova NJ; Gustafson DL; Henthorn TK; Lockerbie O; Merz A; Long M; Morrow M; Ciardiello F; Eckhardt SG
    Clin Cancer Res; 2007 Nov; 13(21):6450-8. PubMed ID: 17975157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KML001, an arsenic compound, as salvage chemotherapy in refractory biliary tract cancers: A prospective study.
    Jo JH; Kang H; Lee HS; Chung MJ; Park JY; Bang S; Park SW; Song SY
    Hepatobiliary Pancreat Dis Int; 2019 Feb; 18(1):62-66. PubMed ID: 30612929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KML001 and doxercalciferol induce synergistic antileukemic effect in acute lymphoid leukemia cells.
    Liu Y; Shin DY; Oh S; Kim S; Koh Y; Kim I
    Oncol Rep; 2017 Jul; 38(1):481-487. PubMed ID: 28586017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of Telomere Integrity and DNA Repair Machineries by KML001 Induces T Cell Senescence, Apoptosis, and Cellular Dysfunctions.
    Cao D; Zhao J; Nguyan LN; Nguyen LNT; Khanal S; Dang X; Schank M; Chand Thakuri BK; Wu XY; Morrison ZD; El Gazzar M; Zou Y; Ning S; Wang L; Moorman JP; Yao ZQ
    Front Immunol; 2019; 10():1152. PubMed ID: 31191531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Tumor Effects of Sodium Meta-Arsenite in Glioblastoma Cells with Higher Akt Activities.
    Lee EJ; Sung JY; Koo KH; Park JB; Kim DH; Shim J; Lee CH; Park J; Kim YN
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33256086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Effect of SN-38 in Combination with Cetuximab on Angiogenesis and Cancer Cell Invasion.
    Pham MH; Delestre L; Dewitte A; Wattez N; Lepretre F; Lansiaux A
    Anticancer Res; 2015 Nov; 35(11):5983-91. PubMed ID: 26504021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-leukemic effect of sodium metaarsenite (KML001) in acute myeloid leukemia with breaking-down the resistance of cytosine arabinoside.
    Yoon JS; Kim ES; Park BB; Choi JH; Won YW; Kim S; Lee YY
    Int J Oncol; 2015 May; 46(5):1953-62. PubMed ID: 25695330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KML001 Induces Apoptosis and Autophagic Cell Death in Prostate Cancer Cells via Oxidative Stress Pathway.
    You D; Kim Y; Jang MJ; Lee C; Jeong IG; Cho YM; Hwang JJ; Hong JH; Ahn H; Kim CS
    PLoS One; 2015; 10(9):e0137589. PubMed ID: 26352139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumoral effect of arsenic compound, sodium metaarsenite (KML001), on multiple myeloma cells.
    Kim SJ; Kim ES; Kim S; Uhm J; Won YW; Park BB; Choi JH; Lee YY
    Int J Oncol; 2017 Dec; 51(6):1739-1746. PubMed ID: 29039521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
    Allegrini G; Goulette FA; Darnowski JW; Calabresi P
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11.
    Rodriguez R; Hansen LT; Phear G; Scorah J; Spang-Thomsen M; Cox A; Helleday T; Meuth M
    Clin Cancer Res; 2008 Sep; 14(17):5476-83. PubMed ID: 18765539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors.
    Kim S; Kim S; Park YS; Park JO; Lim HY; Ahn JS; Lee J; Sun JM; Kang WK; Han R; Kim J; Ahn MJ
    Expert Opin Investig Drugs; 2020 Sep; 29(9):1059-1067. PubMed ID: 32735765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KML001 enhances anticancer activity of gemcitabine against pancreatic cancer cells.
    Yang MH; Lee KT; Yang S; Lee JK; Lee KH; Rhee JC
    Anticancer Res; 2015 Jan; 35(1):183-9. PubMed ID: 25550550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined colonic cancer treatment with vitamin D analogs and irinotecan or oxaliplatin.
    Milczarek M; Rosinska S; Psurski M; Maciejewska M; Kutner A; Wietrzyk J
    Anticancer Res; 2013 Feb; 33(2):433-44. PubMed ID: 23393334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.